THE ROLE OF FLUTICASONE FUROATE/UMECIDINIUM/VILANTEROL IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: ADVANTAGES IN EFFICACY AND TREATMENT ADHERENCE

Abstract

Triple therapy, consisting of an inhaled corticosteroid, a long-acting β₂-agonist, and a long-acting muscarinic
antagonist, is recommended for patients with chronic obstructive pulmonary disease who continue to experience symptoms and non-infectious exacerbations while on treatment with dual bronchodilation. To achieve the best possible treatment outcomes, it is essential to compare the effectiveness of the chosen medication with other triple therapy agents and to select the most convenient inhaler device and dosing regimen for the patient. Studies have shown that treatment with fluticasone furoate/umeclidinium/ vilanterol in a single inhaler provides greater improvements in lung function and reductions of exacerbation and mortality rates compared with other triple therapies. Moreover, once-daily administration is associated with better treatment adherence.